Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...

Pre-earnings options volume in Tempest Therpeutics is normal with calls leading puts 22:1. Implied volatility suggests the market is ...

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...

Tempest Therapeutics has a 52-week low of $0.92 and a 52-week high of $9.00. The stock’s 50 day moving average is $1.33 and its two-hundred day moving average is $2.41.

TPST opened at $1.15 on Friday. Tempest Therapeutics has a 1-year low of $0.92 and a 1-year high of $7.32. The company has a current ratio of 2.17, a quick ratio of 2.17 and a debt-to-equity ratio ...

Tempest Therapeutics reports a six-month improvement in median overall survival for patients in its Phase 1b/2 trial. Phase 3 trial of amezalpat combo therapy for first-line liver cancer treatment ...

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated ...